BioMarin Pharmaceutical Inc. buy UBS Group AG
Start price
20.02.25
/
50%
€65.70
Target price
20.02.26
€108.05
Performance (%)
-30.90%
Price
12.12.25
€45.40
Summary
This prediction is currently active. Massive losses of -30.90% have been the result for the BUY prediction by UBS_Group_AG. This prediction currently runs until 20.02.26. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| BioMarin Pharmaceutical Inc. | -1.003% | -1.003% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by UBS_Group_AG for this prediction
In the thread BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $109.00 to $113.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Stopped prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€51.06
05.08.25
05.08.25
€98.62
05.08.26
05.08.26
-11.09%
12.12.25
12.12.25
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€62.34
30.10.24
30.10.24
€97.65
30.10.25
30.10.25
-28.01%
31.10.25
31.10.25